Merus N.V. (MRUS) surged 37.5 percent to $57.18 on Friday, gaining $15.58 after announcing yesterday encouraging interim results from its Phase II trial of Petosemtamab in combination with Merck's Keytruda for patients with recurrent or metastatic head and neck squamous cell carcinoma.
MRUS opened at $49.69 and ranged between $49.44 and $57.23 in today's session on the Nasdaq. Volume soared to 5.5 million shares, far exceeding its average daily volume of 836,000. The stock previously closed at $41.60.
Over the past 52 weeks, Merus shares have traded between $33.19 and $61.61. A Phase III trial comparing the Petosemtamab-Keytruda combination to Keytruda alone is currently underway.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.